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The van der Schaar Lab has released an alpha version of clairvoyance, a ground-breaking
package that represents the culmination of years of research, development, and real-world
testing. As a uni ed, end-to-end pipeline for time-series data, clairvoyance is unmatched in
its versatility and capability. While primarily developed to aid clinical research and decision
support, clairvoyance can also be used to great effect in non-medical contexts, thanks to its
ability to facilitate complex inference work ows in a transparent, reproducible, and ef cient
manner.
clairvoyance is an enormously important project for our team,
and is the result of years of work across a number of different
areas. It’s the  rst of its kind: an end-to-end pipeline that can
produce personalized and interpretable predictions and
recommendations using time-series data. I have no doubt that
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A crucial breakthrough in the use of time-series data
Time-series data is the bread and butter of evidence-based clinical decision support, as it
offers signi cantly more valuable insight than the “snapshots” presented by static data.
With the increasing availability of electronic patient records, there is enormous untapped
potential to apply machine learning to time-series data, providing accurate and actionable
predictive models for real-world concerns.
At the same time, medical time-series problems in the wild are challenging due to their
highly composite nature. Existing applications of machine learning to such problems have
treated these component tasks as separate problems, leading to a siloed and stylized
development approach that often fails to account for complexities and interdependencies
within the real-world machine learning lifecycle. Regrettably, this has resulted in a
remarkable gap between the inherent capabilities of machine learning methods and their
actual effectiveness in clinical research and decision support.
clairvoyance offers a systematic and full-featured approach to personalized dynamic
predictions, personalized information acquisition, personalized monitoring, and
personalized treatment plans, while also offering interpretations.
clairvoyance will prove useful in driving clinical decision-
making research, and I also believe it can offer a lot of bene ts
to the machine learning community.
– PROF. MIHAELA VAN DER SCHAAR
clairvoyance pipeline
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Under a single, consistent interface, clairvoyance encapsulates all major modeling steps for
time-series data, including: i) loading and (ii) preprocessing patient records, (iii) con guring
problem de nitions, (iv) handling missing or irregular samples in both static and temporal
contexts, (v) conducting feature selection, (vi)  tting prediction models, performing vii)
calibration and (viii) uncertainty estimation of model outputs, (ix) applying global or
instance-wise methods for interpreting learned models, and (x) computing evaluation
metrics.
One solution to 3 problems
Designing real-world project lifecycles poses challenges in terms of engineering (dif cult to
build), evaluation (dif cult to assess), and ef ciency (dif cult to optimize). clairvoyance was
conceived to tackle all of these at once.
The engineering problem is that inference procedures involves signi cant investment, yet
few resources are available for clinical practitioners and domain experts to easily develop
and validate complete work ows. As a software toolkit, clairvoyance enables work ow
development within a single uni ed interface: having modular and composable structures
enables rapid experimentation and deployment by clinical practitioners and engineers alike,
while simplifying collaboration and code-sharing.
The evaluation problem is that, while the performance of each component in the work ow
may depend on the broader context, current empirical practices tend to examine the merits
of each component individually; surrounding steps are largely con gured per convenience
to enforce “all else equal” conditions for assessment. This prevents meaningful assessment
of the performance of the work ow as a whole, and does not meaningfully support
integrated work ow development. As an empirical standard, clairvoyance serves as a
complete experimental benchmarking environment: having a standardized, extensible
pipeline paradigm provides realistic and systematic context for evaluating novel component
models, ensuring that comparisons are fair, transparent, and reproducible.
Existing time-series packages typically concentrate on
implementing algorithms for speci c problems, such as
imputation, dynamic forecasting or feature extraction. By
contrast, clairvoyance enables end-to-end development along
every step of the inference work ow, including components
critical to medical problems.
– DR. JINSUNG YOON (VAN DER SCHAAR LAB; GRADUATED 2020)
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The ef ciency problem is that sophisticated models are resource-intensive to optimize:
State-of-the-art deep learning approaches require many knobs to be tuned—a
computational dif culty compounded by the combination of multiple models, as well as by
potential temporal distribution shifts in time series. Finally, through automated machine
learning, clairvoyance takes care of model con guration and stepwise selection, ef ciently
considering interdependencies among components, algorithms, and time steps.
Estimating personalized treatment effects
Identifying when to give treatments to patients, and how to select among multiple
treatments over time, are important medical problems with a few existing solutions. As
clinical decision-makers are often faced with the problem of choosing between treatment
alternatives for patients, reliably estimating their effects is paramount. An integral aspect of
clairvoyance is the use of a novel counterfactual recurrent network (CRN) approach,
developed by van der Schaar Lab’s researchers, to estimate future treatment outcomes. This
approach leverages recent advances in representation learning and domain adversarial
training to overcome the problems of existing methods for causal inference over time. CRN
achieves this in a manner that is free from the bias introduced by time-varying confounders.
These developments were presented in a session during the 2020 International Conference
on Learning Representations (ICLR 2020); further details can be found here.
Interpretable and actionable outputs
As a group that works extensively with clinicians in formulating problems and developing
solutions, the van der Schaar Lab places particular emphasis on ensuring that models are
interpretable and can be trusted by users without extensive machine learning expertise.
This is an essential factor in being able to narrow the divide between the builders and users
of machine learning models. Interpretability has therefore been built into clairvoyance
through the inclusion of numerous interpretability features including INVASE, an in-house
What is unique here is that we go beyond dynamic forecasting
and provide actionable intelligence by estimating
individualized treatment effects. clairvoyance is capable of
predicting counterfactual trajectories for each patient under
different possible treatment strategies, thus enabling us to
determine when to give treatments to patients and how to
select among multiple treatments over time.
– IOANA BICA (PH.D. STUDENT, VAN DER SCHAAR LAB)
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method that uses actor-critic reinforcement learning methods to help turn black-box
models into white-box models (more information here).
In addition to interpretability, clairvoyance offers con dence estimates, ensuring that users
are given an indication of the degree of certainty accompanying all recommendations or
predictions.
Applications in medicine
clairvoyance is an inherently versatile tool, and can be applied to practically any disease or
condition for which high-quality time-series patient datasets are available. It could also be
adapted beyond a medical setting with relative ease.
Precursors to clairvoyance have been tested and validated using datasets for breast cancer
and cystic  brosis patients, as well as for ICU admission prediction (initially using past
patient data in the U.S. and subsequently using live patient data in the U.K.). Results of
testing have consistently demonstrated predictive capabilities exceeding those of existing
statistical techniques or current state-of-the art machine learning models. A more detailed
analysis of the performance of the current version of clairvoyance can be found here.
One potential application of clairvoyance in the near future could be the current COVID-19
pandemic. While the van der Schaar Lab is already providing AI-enabled predictive tools to
the UK’s National Health Service to help hospital capacity management, clairvoyance could
offer even more comprehensive support for healthcare professionals, including:
– personalized predictions (mortality, discharge, ICU admission [including early warning]
and readmission) and recommendations, both at time of admission and throughout the
period of hospitalization; 
– personalized information acquisition, including estimations of the value of certain
information and determination of which tests should be conducted; 
– personalized monitoring to determine which tests should be conducted and when to make
forecasts, predictions, and treatment recommendations; 
– personalized treatment plans to determine whether, how and when to admit patients to
ICU, to use speci c kinds of mechanical equipment, or to provide medication, as well as the
likely impact of doing so; and 
– transfer learning, enabling i) comparison of disease trajectories for patients before and
after COVID-19, and ii) learning which information acquired from the numerous
trajectories of non-COVID-19 patients can be effectively transferred to COVID-19
patients, and which information cannot.
Say a new patient walks in for something. As a matter of basic
decision support, you’d want to be able to forecast some
indicators, assess possible treatments, and decide what more
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Looking to the future of clairvoyance
clairvoyance alpha is publicly available, and can be downloaded and tested. Development
continues at pace, and the van der Schaar Lab team expects to release a beta version in the
near future, followed by a full release subsequently. Further iterations will continue to be
publicly available at no cost.
It is the research team’s  rm belief that, even in alpha, clairvoyance offers versatility and
integration that cannot be found elsewhere. While today’s announcement marks the release
of the alpha version and a limited amount of supplementary information, further details will
be shared during the coming months.
The alpha software can be found here, and a more thorough introduction to clairvoyance is
available here.
Appendix: clairvoyance compared with related software
Augmented MD  AutoML  Causal inference  COVID-19  Ensemble learning  
Feature selection  Interpretability  Personalized medicine  Reinforcement learning  
Time series analysis  Transfer learning
measurements to take, and when, and to do this preferably
under the same roof.
– DAN JARRETT (PH.D. STUDENT, VAN DER SCHAAR LAB)
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Mihaela van der Schaar
Mihaela van der Schaar is the John Humphrey Plummer Professor of Machine Learning,
Arti cial Intelligence and Medicine at the University of Cambridge, a Fellow at The Alan
Turing Institute in London, and a Chancellor’s Professor at UCLA.
Mihaela has received numerous awards, including the Oon Prize on Preventative Medicine
from the University of Cambridge (2018), a National Science Foundation CAREER Award
(2004), 3 IBM Faculty Awards, the IBM Exploratory Stream Analytics Innovation Award, the
Philips Make a Difference Award and several best paper awards, including the IEEE
Darlington Award.
In 2019, she was identi ed by National Endowment for Science, Technology and the Arts as
the most-cited female AI researcher in the UK. She was also elected as a 2019 “Star in
Computer Networking and Communications” by N²Women. Her research expertise span
signal and image processing, communication networks, network science, multimedia, game
theory, distributed systems, machine learning and AI.
Mihaela’s research focus is on machine learning, AI and operations research for healthcare
and medicine.
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Zhaozhi Qian
After obtaining a MSc in Machine Learning at UCL, Zhaozhi Qian started his career as a data
scientist in the largest mobile gaming company in Europe. Three years later, he found it
might be more ful lling to apply AI to cure cancer than to make the gamers hit the purchase
button 1% more often.
He thus joined the group in 2019 as a PhD student focusing on robust and interpretable
learning for longitudinal data. So far, his work has included inferring latent disease
interaction networks from Electronic Health Records, uncovering the causal structure
between events that unfold over time, and calibrating the predictive uncertainty under
domain shift.
Zhaozhi also worked as a contractor in the NHS during the COVID-19 pandemic
contributing his analytical skills to the national response to the pandemic.
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Dan Jarrett
Dan is a second-year Ph.D. student in the machine learning and arti cial intelligence
research group at the department of mathematics, advised by Professor van der Schaar.
He graduated from Princeton University with a B.A. in economics, and from Oxford with an
MSc. in computer science.
He has professional experience in  nance, consulting, and technology spaces, and research
interests include representation learning and decision-making over time.
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Ioana Bica
Ioana Bica is a second year PhD student at the University of Oxford and at the Alan Turing
Institute. She has previously completed a BA and MPhil in Computer Science at the
University of Cambridge where she has specialised in machine learning and its applications
to biomedicine.
Ioana’s PhD research focuses on building machine learning methods for causal inference
and individualised treatment effect estimation from observational data. In particular, she
has developed methods capable of estimating the heterogeneous effects of time-dependent
treatments, thus enabling us to determine when to give treatments to patients and how to
select among multiple treatments over time.
Recently, Ioana has started working on methods for understanding and modelling clinical
decision making through causality, inverse reinforcement learning and imitation learning.
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Spotlight on organ transplantation research projects
In this post, we explain how organ transplantation presents a web of complex problems
and introduce our cutting-edge machine learning methods.
Mihaela van der Schaar James Jordon Jeroen Berrevoets Nick Max eld  4 days ago

    
EVENTS NEW PUBLICATION NEWS
van der Schaar Lab at ICML 2021: 4 papers accepted
The van der Schaar Lab's researchers will publish 4 papers at ICML 2021, the leading
international academic conference in machine learning.
Nick Max eld  May 10, 2021
EVENTS VIDEO
Revolutionizing Healthcare: second roundtable on
interpretability in ML/AI for healthcare
The van der Schaar Lab’s seventh...
Nick Max eld  May 3, 2021
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